两种组织型转谷氨酰胺酶PET示踪剂在原位肿瘤异种移植模型中的体内评价
在乳腺癌MDA-MB-231肿瘤异种移植模型中,[11C]1肿瘤摄取低(40-60分钟约0.5 %ID/g)且洗脱较快,[18F]2肿瘤摄取随时间稳定升高(40-60分钟约1.7 %ID/g)。预先给予TG2抑制剂ERW1041E可降低肿瘤放射性浓度,使用未标记2时抑制效果增强。作者认为[11C]1在该模型中靶向TG2的潜力似乎不足,而[18F]2实现了TG2靶向,可用于未来研究。
要点
- [11C]1肿瘤摄取低且洗脱较快,在该模型中靶向TG2的潜力似乎不足。
- [18F]2肿瘤摄取随时间稳定升高,实现了TG2靶向。
- 预先给予ERW1041E可降低肿瘤放射性浓度,使用未标记2时抑制效果增强。
核心结论
- [11C]1在该模型中靶向TG2的潜力似乎不足,而[18F]2实现了TG2靶向。
- 作者认为[18F]2可用于未来研究以阐明活性组织型转谷氨酰胺酶在疾病中的作用。
研究设计与样本
- 在乳腺癌(MDA-MB-231)肿瘤异种移植模型中进一步评价两种放射性标记的不可逆TG2抑制剂。
主要发现
- [11C]1和[18F]2在SCID小鼠中的代谢稳定性与先前报道的Wistar大鼠中的稳定性相当。
- 对MDA-MB-231细胞和分离肿瘤的定量实时聚合酶链反应分析显示TG2高表达,其他转谷氨酰胺酶表达很低。
- PET显像显示[11C]1肿瘤摄取低(注射后40-60分钟约0.5 %ID/g)且洗脱相对较快。
- [18F]2肿瘤摄取随时间稳定升高(注射后40-60分钟约1.7 %ID/g)。
- 预先给予TG2抑制剂ERW1041E可降低肿瘤放射性浓度,使用未标记2时该抑制效果增强。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The protein cross-linking enzyme tissue transglutaminase (TG2; EC 2.3.2.13) is associated with the pathogenesis of various diseases, including cancer. Recently, the synthesis and initial evaluation of two high-potential radiolabelled irreversible TG2 inhibitors were reported by us. In the present study, these two compounds were evaluated further in a breast cancer (MDA-MB-231) tumour xenograft model for imaging active tissue transglutaminase in vivo. RESULTS: The metabolic stability of [11C]1 and [18F]2 in SCID mice was comparable to the previously reported stability in Wistar rats. Quantitative real-time polymerase chain reaction analysis on MDA-MB-231 cells and isolated tumours showed a high level of TG2 expression with very low expression of other transglutaminases. PET imaging showed low tumour uptake of [11C]1 (approx. 0.5 percentage of the injected dose per gram (%ID/g) at 40-60 min p.i.) and with relatively fast washout. Tumour uptake for [18F]2 was steadily increasing over time (approx. 1.7 %ID/g at 40-60 min p.i.). Pretreatment of the animals with the TG2 inhibitor ERW1041E resulted in lower tumour activity concentrations, and this inhibitory effect was enhanced using unlabelled 2. CONCLUSIONS: Whereas the TG2 targeting potential of [11C]1 in this model seems inadequate, targeting of TG2 using [18F]2 was achieved. As such, [18F]2 could be used in future studies to clarify the role of active tissue transglutaminase in disease.
引用
- van der Wildt B, Wilhelmus MMM, Beaino W, et al. In vivo evaluation of two tissue transglutaminase PET tracers in an orthotopic tumour xenograft model. EJNMMI Res. 2018. PMID: 29802556. doi:10.1186/s13550-018-0388-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。